Actively Recruiting
Open-label Study of FMK-0947 PET Imaging to Assess Brain Alpha-Synuclein in Parkinsons Disease and Healthy Elderly Participants
Led by XingImaging, LLC · Updated on 2026-10-19
18
Participants Needed
1
Research Sites
N/A
Total Duration
AI-Summary
What This Trial Is About
Researchers are evaluating alpha-synuclein ASYN deposition in the brains of people with Parkinsons disease PD compared to healthy elderly HE individuals. This open-label study aims to measure brain uptake and pharmacokinetics of the drug FMK-0947 using positron emission tomography PET imaging, assessing its potential to quantify alpha-synuclein pathology in PD. The study includes up to 18 participants, with 12 having PD and 6 being healthy elderly volunteers. Participants will receive up to two single intravenous injections of FMK-0947. After each injection, dynamic PET imaging will be performed using either a high-resolution United Imaging NeuroEXPLORER NX PET scanner, a standard Siemens Biograph mCT PET scanner, or both. The study has two parts Part 1A involves the initial injection and PET scan, while Part 1B may include a second injection and scan on the alternate PET scanner. Throughout the study, participants will undergo safety assessments and brain imaging evaluations over about one year. Researchers will track brain uptake of FMK-0947, measure standardized uptake value ratios SUVR, and monitor adverse events. The study compares imaging results between PD and healthy elderly groups to better understand alpha-synuclein deposition and assess the safety of the investigational drug.
CONDITIONS
Brief Title
MK-0947 PN-002: An Open-label Study to Evaluate Brain α-synuclein Deposition Using Positron Emission Tomography (PET) and [¹⁸F]MK-0947 in Participants With Parkinson's Disease (PD)
Research Team
A
Anna Carberry
Not the Right Trial for You?
Explore thousands of other clinical trials that might be a better match.
Sign up to get personalized trial recommendations delivered to your inbox.
Already have an account? Log in here